

LIVING WITH LUPUS IN 2020

COUNTRY LEVEL DATA

Germany



DATA FOR: **Germany**

Publication: http://dx.doi.org/10.1136/lupus-2020-000469

COUNTRY: Germany

COUNTRY:	Germany				
		DEMOGRA	APHICS:		
	Germany	<u>EUROPE</u>	<u>Age</u>	<u>Germany</u>	EUROPE
Total number of responses	301	4375	Up to 25	8.0%	6.4%
			26 to 35	19.9%	17.9%
<u>Gender</u>	<u>Germany</u>	<u>EUROPE</u>	36 to 45	25.2%	27.4%
Man	3.7%	3.7%	46 to 55	29.9%	26.6%
Woman	96.0%	95.6%	56 to 65	12.3%	14.8%
Other / prefer not to answer	0.3%	0.7%	above 65	3.0%	5.1%
Total	100.0%	100.0%	NA	1.7%	1.8%
			Grand Total	100.0%	100.0%
		DIAGNO	OSIS		
<u>Diagnosis</u>	Germany	<u>EUROPE</u>	Time to Diagnosis	<u>Germany</u>	<u>EUROPE</u>
SLE	95.0%	94.4%	Within the year	26.9%	26.5%
Child onset SLE	5.0%	5.6%	1 year	17.5%	21.1%
Grand Total	100.0%	100.0%	2 years	11.9%	11.5%
			3 years	5.9%	5.7%
Prior Diagnosis received before "Lupus"	<u>Germany</u>	<u>EUROPE</u>	4 years	4.5%	4.6%
None	47.2%	53.7%	5 years	3.8%	4.4%
UCTD/MCTD	2.0%	6.7%	6 years	3.1%	2.9%
Sjogren	4.3%	4.7%	7 years	2.8%	2.7%
APS	1.3%	2.4%	8 years	2.4%	2.4%
Other Autoimmune or Rheumatic	15.0%	13.8%	9 years	1.7%	2.3%
Fibromyalgia	6.0%	5.8%	10 to 20 years	12.9%	10.4%
Psychologic or mental disorder	16.3%	8.9%	More than 20 years	6.3%	5.5%
Other prior diagnosis	19.6%	16.5%	Grand Total	100.0%	100.0%
n=	291	4,275	n=	286	4,154



DATA FOR: **Germany**

Publication: http://dx.doi.org/10.1136/lupus-2020-000469

IMPACT ON STUDIES & CAREER							
Education level	<u>Germany</u>	<u>EUROPE</u>	Employment level	Germany	EUROPE		
Basic	9.8%	3.7%	Employed full time	29.5%	34.6%		
Secundary	69.5%	53.9%	Employed part time	27.8%	16.5%		
Academic	20.7%	42.5%	Self-employed full time	0.7%	3.0%		
n=	285	4,150	Self-employed part time	1.4%	2.4%		
			Looking for employment	2.0%	5.1%		
Economic profile	<u>Germany</u>	<u>EUROPE</u>	Stopped work for medical reason	13.2%	14.7%		
No difficulties paying all bills	53.2%	46.9%	Retired	12.2%	11.6%		
Occasional difficulties paying all bills.	21.3%	26.8%	Student	4.1%	4.0%		
Often difficulties paying all bills	8.6%	10.4%	No paid employment / Full time home	6.1%	4.7%		
Always difficulty paying all bills	5.6%	7.1%	Other / prefer not to answer	3.1%	3.5%		
Did not respond	11.3%	8.9%					
n=	301	4375	n=	295	4247		
IMPACT ON STUDIES	Germany	<u>EUROPE</u>	IMPACT ON CAREER	Germany	EUROPE		
Chose more relevant studies	1.7%	3.1%	No impact	25.9%	32.5%		
could not do what they wanted	12.9%	11.1%	Changed career/ job	12.9%	13.5%		
needed special support and received it	4.7%	4.6%	moved to Flexible hours	8.6%	8.1%		
needed support but did NOT receive it	3.1%	2.9%	Reduced Work Schedule	26.3%	18.5%		
Overall negative effect	15.3%	13.5%	Stopped work, gets social allowances	15.5%	18.5%		
Overall positive effect	1.0%	1.4%	Missed promotion opportunities	18.0%	9.5%		
No impact	70.5%	69.8%	Employment was terminated	7.2%	8.4%		
			Other negative impact	30.2%	20.8%		
n=	295	4240	Other positive impact	1.4%	1.8%		
			Overall had negative impact	68.0%	57.9%		
			n=	278	4024		



DATA FOR: **Germany**

Publication: http://dx.doi.org/10.1136/lupus-2020-000469

			IMPACT ON SOC	CIAL / FAMILY		
<u>Civil status</u>		Germany	<u>EUROPE</u>	Have children	Germany	EUROPE
Child/young with family		5.6%	4.5%	None	43.8%	32.8%
Single		15.7%	17.4%	One child	22.2%	23.8%
Married / with partner		67.2%	66.9%	2 or more children	28.6%	38.9%
Divorced		9.4%	9.2%	Child/young living with family	5.4%	4.5%
Widowed		2.1%	2.0%			
	n=	287	4206	n=	297	4288
Would have liked more children		Germany	EUROPE	Faced Misscariages	<u>Germany</u>	EUROPE
A. Yes		33.8%	37.6%	A. One miscarriage	12.2%	18.4%
B. No		42.9%	37.7%	B. Some miscarriages	4.2%	8.5%
C. don't know / prefer not to answer		23.3%	24.7%	C. Many miscarriages	1.5%	2.9%
				D. No miscarriage	82.1%	70.2%
n (women	only) =	266	3,645	n (women only) =	263	3,756
Difficulty to cope with Daily activities		Germany	EUROPE	More or less active than others same age	<u>Germany</u>	<u>EUROPE</u>
No Problem at all 1		15.9%	16.2%	Less active due to lupus	76.3%	72.6%
2		29.8%	32.3%	Equally active	11.5%	15.6%
3		40.1%	34.3%	More active due to lupus	4.5%	3.6%
4		12.8%	15.4%	I don't know	7.7%	8.1%
Fully Unable 5		1.4%	1.8%			
	n=	289	4226	n=	287	4212
Impact on Sexual/emotional life		Germany	EUROPE	Negative Impact on couple	Germany	EUROPE
Negative impact		41.3%	38.2%	It created tensions	50.0%	33.2%
Mixed Positive and negative		39.9%	36.2%	It is difficult for me	67.6%	68.4%
No significant impact		18.1%	23.9%	It is difficult for my partner	41.9%	26.7%
Positive impact		0.7%	1.6%	I am concerned for my couple	18.1%	13.2%
				Our relationship ended	16.2%	16.6%
	n=	288	4,204	n=	210	2875



DATA FOR: **Germany**

Publication: http://dx.doi.org/10.1136/lupus-2020-000469

n=

285

4197

			D.	CEACE ACTIVITY		
			DI	SEASE ACTIVITY		
Lupus was under control past 3 mont	: <u>hs</u>	Germany	<u>EUROPE</u>	Number of symptoms (list of 23)	Germany	EUROPE
Yes		69%	72%	1	0.7%	1.6%
No		31%	28%	2	2.8%	2.1%
				3	2.1%	4.4%
	n=	301	4347	4	4.6%	5.9%
				5	5.6%	6.1%
				6	6.3%	8.5%
		Germany	<u>EUROPE</u>	7	11.2%	9.3%
Average nr of symptoms (list of 23)		8.9	8.8	8	13.0%	10.4%
	n=	285	4197	9	11.9%	10.1%
				10	10.5%	9.3%
				11	9.1%	8.3%
		Germany	<u>EUROPE</u>	12	5.3%	7.0%
Median number of symptoms		9	9	13	6.3%	5.8%
	n=	285	4197	14	7.7%	4.4%
				15	1.4%	2.7%
				16	1.1%	2.1%
				17	0.4%	1.1%
				18	0.0%	0.4%
				19	0.0%	0.3%
				20	0.0%	0.0%



DATA FOR: **Germany**

Publication: http://dx.doi.org/10.1136/lupus-2020-000469

Symptoms or Features experienced / Most bothersome

Г	Germa	anv		EURO) PF
l	Regularly	Top 3 most		Regularly	Top 3 most
Patient reported Symptoms or features	experience	bothersome	Patient reported Symptoms or features	experience	bothersome
A. Rash	37%	10%	A. Rash	40%	9%
B. Sun sensitivity	74%	26%	B. Sun sensitivity	69%	23%
C. Mouth ulcers	22%	1%	C. Mouth ulcers	35%	3%
D. Dryness in the mouth or eyes	62%	9%	D. Dryness in the mouth or eyes	55%	9%
E. Dryness of the skin	67%	3%	E. Dryness of the skin	57%	4%
F. Hair loss	51%	12%	F. Hair loss	53%	14%
G. Pain / swelling in joints	80%	48%	G. Pain / swelling in joints	77%	49%
H. Jaccoud (hand deformation) or tendons a	12%	2%	H. Jaccoud (hand deformation) or tendor	14%	4%
I. Muscle Pain/Weakness	70%	33%	I. Muscle Pain/Weakness	68%	33%
J. Headaches or migraine	53%	16%	J. Headaches or migraine	51%	17%
K. Fatigue and weakness	90%	59%	K. Fatigue and weakness	85%	55%
L. Flu-like symptoms/Fevers	25%	6%	L. Flu-like symptoms/Fevers	28%	4%
M. Shortness of breath	38%	7%	M. Shortness of breath	32%	6%
N. Depression or Anxiety	41%	19%	N. Depression or Anxiety	44%	17%
O. Haematologic problems incl. anemia	23%	5%	O. Haematologic problems incl. anemia	27%	4%
P. Poor circulation or Raynauds	43%	7%	P. Poor circulation or Raynauds	45%	8%
Q. Kidney problems	27%	13%	Q. Kidney problems	20%	11%
R. Chest pain	19%	3%	R. Chest pain	24%	4%
S. High Blood pressure	28%	6%	S. High Blood pressure	23%	4%
T. Stroke, mini-stroke, Blood clots	7%	2%	T. Stroke, mini-stroke, Blood clots	9%	4%
U. Osteoporosis	20%	2%	U. Osteoporosis	19%	5%
n=	301	279	n=	4375	4084



DATA FOR: **Germany**

Publication: http://dx.doi.org/10.1136/lupus-2020-000469

			MEDICA	ATION		
		<u>Germany</u>	<u>EUROPE</u>		<u>Germany</u>	<u>EUROPE</u>
Average number of medication (from li	<u>ist</u>			Median number of medication (from		
<u>of 16)</u>		5.2	5.2	<u>list of 16)</u>	5	5
	n=	278	4099	n=	278	4099
Number of medications (list of 16)		<u>Germany</u>	<u>EUROPE</u>	% using given medication type:	Germany	EUROPE
	1	5.4%	5.4%	Non Steroids Anti-Inflammatory	41.0%	32.9%
	2	7.6%	9.0%	Antimalarials	71.6%	75.0%
	3	10.1%	12.5%	Oral Steroids	58.3%	52.4%
	4	14.7%	14.1%	Immunosuppressants	54.3%	39.8%
	5	17.6%	14.8%	Biologics	14.4%	10.9%
	6	14.0%	13.9%	Painkillers	37.8%	50.1%
	7	14.0%	11.8%	Antidepressant	12.2%	17.0%
	8	9.0%	9.0%	Anxiolytic	4.0%	11.7%
	9	5.4%	5.1%	Anticoagulants	6.5%	16.6%
	10	1.8%	2.5%	Thyroid medication	27.3%	14.8%
	11	0.4%	1.1%	Blood circulation and heart	39.2%	23.3%
	12	0.0%	0.4%	Stomach protection	41.4%	47.0%
	13	0.0%	0.2%	Statins	1.1%	5.9%
				Calcium	9.7%	29.7%
	n=	278	4099	Vitamin D	81.3%	68.4%
				Vitamins (excl.D) / mineral complements	22.7%	25.4%



DATA FOR: **Germany**

Publication: http://dx.doi.org/10.1136/lupus-2020-000469

ACCESS / Quality of life (scale of 1 to 5)

I have appropriate access to	<u>(</u>	<u>Germany</u>	EUROPE	HrQoL dimensions	Germany	EUROPE	
Average scores (1 Fully dis	sagree - 5 f	fully agree)		AVERAGE SCORES (1=FULLY ABLE, 5= FULLY UNABLE)			
Experienced lupus doctors		3.69	3.81	Mobility	2.19	2.22	
Multidisciplinary team		3.36	3.28	Self care	1.59	1.71	
Specialised nurses that know lupus		2.79	2.92	Daily Activities	2.54	2.54	
Prescribed medication		4.10	4.08	Pain or discomfort	3.04	3.14	
Affordable treatments		3.51	3.77	Anxiety or depression	2.71	2.96	
Social support and benefits		3.02	2.78	Average	2.41	2.51	
Physiotherapy, Rehab, Occupational Tl	hera	3.17	2.77				
Professional psychological support		2.99	2.68				
n	min	218	3126	n min	287	4196	
n ı	max	267	3842	n max	291	4240	
Worry about lupus progressing?	<u>(</u>	<u>Germany</u>	EUROPE				
Very Low (1-2)		5.5%	3.6%				
Low (3-4)		16.8%	9.3%				
Mid (5-6)		32.2%	24.5%				
High (7-8)		33.3%	41.0%				
Very high (9-10)		12.1%	21.6%				
	n=	273	4042				



DATA FOR: **Germany**

Publication: http://dx.doi.org/10.1136/lupus-2020-000469

Impact of lupus not being under control over past 3 months

	% (of Health Related	l OoL Maintaine	ed vs 100% = FULL HEALTH/ABILITY TO PERFORM		
	<u> </u>	Germa			<u>EURO</u>	<u>PE</u>
		lupus under	not under		lupus under	not under
		control	<u>control</u>		control	control
Mobility		75%	60%	Mobility	73%	59%
Self care		89%	76%	Self care	86%	73%
Daily Activities		67%	49%	Daily Activities	66%	51%
Pain or discomfort		54%	37%	Pain or discomfort	51%	35%
Anxiety or depression		60%	51%	Anxiety or depression	54%	44%
Average		69%	55%	Average	66%	52%
ı	n min	201	86	n min	3011	1179
r	n max	203	88	n max	3042	1194
		Germa	nv		EURO	PE
		lupus under	not under	More or less active than others of same	lupus under	not under
More or less active than others of same a	ige	control	control	age	control	control
Less active due to lupus		72.9%	84.1%	Less active due to lupus	68.6%	83.0%
Equally active		14.1%	5.7%	Equally active	18.8%	7.6%
More active due to lupus		4.5%	4.5%	More active due to lupus	4.0%	2.7%
I don't know		8.5%	5.7%	I don't know	8.7%	6.7%
	n=	199	88	n=	3018	1189
		Germa	ny		EURO	PE
		lupus under	not under		lupus under	not under
Impact on Sexual/emotional life		control	control	Impact on Sexual/emotional life	control	control
Negative impact		35.5%	54.5%	Negative impact	34.0%	49.0%
Mixed + and -		43.0%	33.0%	Mixed + and -	36.4%	35.7%
No significant impact		20.5%	12.5%	No significant impact	27.8%	14.1%
Positive impact		1.0%	0.0%	Positive impact	1.8%	1.2%
·	n=	200	88	n=	3018	1181



DATA FOR: **Germany**

Publication: http://dx.doi.org/10.1136/lupus-2020-000469

IMPACT OF A PROMPT DIAGNOSIS

% of Health Related QoL Maintained vs 100% = FULL HEALTH/ABILITY TO PERFORM

	Germ	any		EURC	<u>DPE</u>
		<u>Diagnosed</u>		<u>Diagnosed</u>	<u>Diagnosed</u>
	<u>Diagnosed</u>	after more		within 2	after more
	within 2 years	than 5 years		<u>years</u>	than 5 years
Mobility	75%	63%	Mobility	75%	62%
Self care	87%	82%	Self care	86%	76%
Daily Activities	68%	54%	Daily Activities	67%	53%
Pain or discomfort	53%	44%	Pain or discomfort	52%	39%
Anxiety or depression	61%	54%	Anxiety or depression	52%	49%
Average	69%	59%	Average	66%	56%
Difference		-10%	Difference		-10%
of which - explained by age (*)		-3%	of which - explained by age		-3%
n min	122	91	n min	1926	1239
n max	125	92	n max	1951	1249
average age:	40.2	47.7		41.2	49.0


^(*) in our overall study, we found that from age 28 to age 63 HrQOL drops from 69.1% to 56.0% i.e. 3.7% per decade





DATA FOR: **Germany**


Publication: http://dx.doi.org/10.1136/lupus-2020-000469

DATA FOR: 0












DATA FOR: **Germany**

Publication: http://dx.doi.org/10.1136/lupus-2020-000469

DATA FOR: 0







Living with lupus in 2020 - Country level data

DATA FOR: 0

For full text european analysis, please refer to:

Cornet A, Andersen J, Myllys K, et al. Living with systemic lupus erythematosus in 2020: a European patient survey. Lupus Science & Medicine 2021;8:e000469. doi:10.1136/lupus-2020-000469

For more informatioin, contact: secretariat@lupus-europe.org